Focus

​We believe that integrating the power of AI into healthcare diagnostics represents the future of medicine.
​
We invest in companies that allow doctors to diagnose patient illnesses

• ​earlier
• more accurately
• less expensively
• less invasively​

Our portfolio companies achieve faster time to proof-of-concept with less money spent getting there.

​A Game-Changer in the Investment World

DigitalDx Ventures is a majority woman-owned impact fund investing in early-stage health technology companies that deliver innovative solutions using artificial intelligence (AI) to better diagnose + treat illness.

DELIVERED OUTCOMES
Fund I Value of Investments Increased 28.8% in 24 Months

• DigitalDx Ventures has closed its first fund, putting $21.7+ million to work in 8 portfolio companies.
• Fund I portfolio companies are marked up only upon new investment rounds with third parties.

Leveraging Women in Leadership

• More than half of the DDx portfolio companies have women founders or women in the C-suite.
• Six women were added to the portfolio company boards and 1 to the C-suite since 2019.
• 50% of the Limited Partners in Fund 1 are women.

Seasoned Team of Professionals: Diverse + Experienced

• Our five-person team leverages decades of success in medicine, science, technology, finance, and law, and views over 80 companies per month to identify, diligence, invest, grow, and exit game-changing diagnostic companies.

Focus

"We believe the combination of big data +
artificial intelligence
is the future of personalized medicine."

DigitalDx Ventures I, L.P. is focused on investments that help doctors better understand their patients’ condition and make more personalized and effective treatment decisions. Simply stated, this is the future of medicine. It is the largest opportunity emerging in the big data field of medicine. Few VCs truly understand the value of this area. Our team does, and is the leading force behind the most successful companies in this field. The principals have already demonstrated the ability to find, support and create enormous value on both the venture and company sides. For example, our Team was early in utilizing genomic testing and the process of using CLIA lab certification to provide Laboratory Developed Tests to patients and providers more quickly, eliminating the delays and costs commonly associated with FDA approval. Not only healthcare providers, but also payers support this type of clinical testing for its cost-effective benefits.

The practice of Medicine has changed dramatically in the past twenty years. Doctors have gone from not enough data on a patient, to far too much data to understand. As a patient’s genomes, epigenomes and microbiomes become more important, a doctor now must understand billions of data points to effectively diagnose and treat each patient individually. As medicine becomes increasingly personalized, solutions for every patient are different: drug susceptibility and effectiveness vary with every patient, every cancer is different as it grows rapidly and haphazardly, and every pathogen is adapting to antibiotics and finding a way around them. As we better understand our bodies at the molecular level, we start to appreciate our true complexity.

This means that diagnostics is becoming increasingly important to the practice of medicine. Medicine has become a “big data” field. Every treatment needs to be personalized to that particular patient’s uniqueness. Some drugs will work for an individual patient, while other drugs will not work. A patient’s microbiome will change every day as they eat different foods. This means a patient’s uniqueness won’t even stand still; important parts will be changing all the time. And as such, diagnostics and treatment must also change and evolve.

​The amount of information coming from our blood, saliva, fecal matter and urine is vast and can indicate serious illnesses well before the patient, or doctor, even thinks to investigate. The typical human body contains 100 trillion cells, each with 3+ billion DNA base pairs, harboring life critical information we need to harness, parse and interpret. Each individual has even more microbiome elements living inside their bodies and influencing their health. Doctors need help from Artificial Intelligence to sort out the vast amount of data on every patient if we are to get out in front of these diseases and be more effectively proactive in health and wellness.

Investment Evaluation Intelligence

Working with a world renowned expert on Artificial and Decision Intelligence, the DigitalDx Ventures team has internally developed an investment decision-making model called the Investment Tool for Expert Diagnostics ("iTED") to capture all relevant factors in evaluating potential investments, encourage greater adherence to key principles of successful outlier companies, and create discipline to aid in the consistency and scalability of analysis.

iTED includes key social impact elements such as:

• The diversity of company executive teams and board members
• The scale of the health problem addressed (i.e., how many people affected) because DigitalDx Ventures is focused on large population problems
• Whether the solution is comparably less invasive, which results in reduced regulatory requirements, lower costs and, by extension, more accessible healthcare.

Portfolio Companies

DigitalDx Ventures invests in companies focused on impacting health with diagnostics for conditions that include breast cancer, mental health, kidney health, maternal health, multi-cancer screening, and brain health (with the first indication in Alzheimer's).